Antibody-Granzyme B Fusion Protein

Creative Biolabs has decades of experience in developing and manufacturing various effective antibodies, now our professional scientists and advanced platforms will be available to provide customers antibody-enzyme conjugate strategy. Here, we offer high-quality antibody-granzyme B protein fusion service in cost-effective manners for immunotherapy.

Granzyme B

Granzymes are serine proteases that exist in the granules of cytotoxic lymphocytes (CTLs), natural killer cells (NK cells) and cytotoxic T cells. Recently, Granzyme B has also been found to be produced by a wide range of non-cytotoxic cells ranging from basophils and mast cells to smooth muscle cells. The function of granzyme is dependent on the presence of perforin, which establishes pores in the cell membrane to facilitate the entry of granzymes into the cell. There are five classes of human granzymes, of which GrB was found to be the most potent functionally and acts as an effective cytotoxic when linked to antibodies or growth factors (e.g., VEGF). GrB plays a critical role in stimulating multiple apoptotic pathways including directly activating caspases, inducing DNA fragmentation, activating the mitochondrial death pathway, and/or directly cleaving the nuclear matrix.

Fig.1 The Granzyme B-perforin cytotoxic pathway. (Hiebert, 2012)

Antibody-Granzyme B Fusion Protein

Granzyme B has shown to be cytotoxic to a variety of tumors, including tumor vasculature, carcinomas, acute myeloid leukemia, and melanoma. The fusion protein was also found to retain the natural catalytic activity of GrB. Some in vivo studies revealed that the fusion protein was capable of inhibiting tumor growth and sensitizing the tumor cells to chemotherapy and radiotherapy. The utilization of GrB antibody proteins for cancer therapy is a promising therapeutic strategy. However, the challenges also exist for future development and clinical application of GrB antibody proteins such as the presence of the endogenous inhibitor, intracellular serpin protease inhibitor.

Fig 2. Cellular uptake of granzyme B and targeted granzyme B fusion proteins. (Oberoi, 2013)

Creative Biolabs is dedicated to helping you develop antibody-granzyme B fusion protein by using readily available or customized strategies. We provide our clients with a wide range of antibody-enzyme conjugate services. Please contact us for more information and a detailed quote.

References

1. Hiebert, P. R.; Granville, D. J. Granzyme b in injury, inflammation, and repair. Trends in Molecular Medicine. 2012, 18(12), 732-741.
2. Oberoi, P.; et al. Selective induction of cancer cell death by targeted granzyme B. Antibodies. 2013, 2(1), 130-151.

For Research Use Only. NOT FOR CLINICAL USE.